During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

In April 2024, Barinthus Bio announced topline results from the Phase 1b/2 APOLLO dose-ranging trial (also known as HPV001) ...

SHANGHAI, China I March 23, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1 ...

Stein, MD, professor and co-director of the Acute Leukemia Program at City of Hope in Duarte, California, provides deeper insight into the trial design and key findings in an interview with Targeted ...

The recommended phase 2 dose (RP2D) of BMS-813160 was established in the 3+3 design. Primary endpoints were safety and ... No grade 3/4 toxicities attributed to nivolumab or BMS-813160 were identified ...

By Tom Delavan With its radical buildings by Eliel Saarinen and Alvar Aalto, the Finnish capital is one of Europe’s most fascinating, if lesser-sung, design capitals. By Michael Snyder The ...

Our art critic goes room-by-room through New York’s Gilded Age house museum, reopening after nearly five years. Don’t miss the new upstairs galleries. By Holland Cotter The darkly comic ...

including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab as a fixed-dose combination with its PD-1 inhibitor Opdivo (nivolumab) – under the Opdualag brand name – in patients ...

Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows ...